A Priority Review Voucher is a transferable entitlement granted by a regulatory agency that entitles the holder to an expedited review process for a future drug application, distinguishing it from standard regulatory pathways by providing a time-reduced evaluation for qualifying therapeutic products.
24
Publications
836
Citations
51
Authors
30
Institutions
Publications per year
2017–2026
10
Parents
Publications
24
Developing Drugs For Developing Countries
David B. Ridley, Henry G. Grabowski, Jeffrey L. Moe · Health Affairs · 2006 · 199 citations · Full text
2022 FDA TIDES (Peptides and Oligonucleotides) Harvest
Othman Al Musaimi, Danah Al Shaer, Fernando Alberício et al. · Pharmaceuticals · 2023 · 62 citations · Full text
1–5 of 24
Authors
51
- DB
4
h-index
- AS
4
h-index
- HG
3
h-index
- AT
2
h-index
- TJ
2
h-index
1–5 of 51
Institutions
30
Duke University
Durham, United States
5 h-index
7 publications
540 citations
Brigham and Women's Hospital
Boston, United States
3 h-index
8 publications
218 citations
Imperial College London
London, United Kingdom
2 h-index
4 publications
110 citations
Universitat de Barcelona
Barcelona, Spain
2 h-index
3 publications
94 citations
Novartis (Switzerland)
Basel, Switzerland
1 h-index
1 publications
37 citations
Evotec (United Kingdom)
Abingdon, United Kingdom
1 h-index
1 publications
62 citations
University Health Network
Toronto, Canada
1 h-index
1 publications
18 citations
Scripps Research Institute
San Diego, United States
1 h-index
1 publications
45 citations
1–8 of 30
Venues
- Health Affairs
4 publications · 289 citations
4
h-index
- JAMA
2 publications · 58 citations
2
h-index
- PLoS neglected tropical diseases
2 publications · 53 citations
2
h-index
- The Lancet
1 publications · 33 citations
1
h-index
- Biosecurity and Bioterrorism Biodefense Strategy Practice and Science
1 publications · 19 citations
1
h-index
1–5